SP100 and GP210 Antibodies, IgG, Serum
Use
The test is useful for evaluating the risk of primary biliary cholangitis (PBC) in anti-mitochondrial antibody (AMA)-negative patients through the identification of SP100 and GP210 antibodies. It also assists in estimating risk in AMA-positive patients with incomplete disease features. The presence of these antibodies provides critical serological support for diagnosing PBC, especially in cases lacking clear clinical or phenotypic attributes, and it can offer prognostic information regarding liver disease progression.
Special Instructions
Not provided.
Limitations
The presence of anti-SP100 and anti-GP210 antibodies does not exclusively confirm the etiology or prognosis of primary biliary cholangitis and should not be solely relied upon. A negative result for these antibodies does not exclude a diagnosis of PBC. The results should be interpreted in conjunction with clinical findings and other serological evaluations. The expression of multiple nuclear dot and nuclear envelope patterns may not be identifiable in the presence of other antibodies.
FDA ApprovedNew York Approved
Methodology
Immunoassay (ELISA)
Biomarkers
GP210
ProteinSP100
Protein
LOINC Codes
- 106055-7 - SP100 and GP210 Ab.IgG pnl SerPl
- 96565-7 - sp100 Ab Ser IA-aCnc
- 96560-8 - Nuclear pore prot gp210 Ab Ser IA-aCnc
Result Turnaround Time
2-8 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
1.0 mL
Minimum Volume
0.4 mL
Container
Plastic vial
Collection Instructions
Centrifuge and aliquot serum into a plastic vial.
Causes for Rejection
Heat-treated specimen
Stability Requirements
| Temperature | Period |
|---|---|
| Refrigerated | 21 days |
| Frozen | 21 days |